>Objective: In this study, we aimed to compare the effect(s) of zinc sulphate on growth and serum iron variables when it is given with ferrous sulphate in iron deficiency anemia (IDA).>Materials and Methods: Patients (n=79) were randomly divided into two groups. In one group (n=40) 4 mg/kg/d ferrous sulfate was given orally. In the other group (n=39), in addition to ferrous sulfate, 5 mg/d oral zinc sulfate was given.>Results: Compared to the initial values statistically significant increase in mean height, weight, and head circumference has been observed in both groups after 3 months. However, there was no statistical difference between two groups concerning mean height, weight, and head circumference at the beginning (83.43±11.3 cm vs 84.62±12.77 cm; 12.36±3.08 kg vs 12.72±3.87 kg; 47.33±2.15 cm vs 47.26±2.73 cm, respectively), at the first month, (84.82±10.97 vs 85.97±12.28; 12.78±3.09 vs 13.09±3.87; 47.76±2.10 vs 47.61±2.67, respectively), and at the third month, (86.4±11.12 vs 87.69±12.13; 12.9±3.06 vs 13.35±3.81; 48.22±1.89 vs 48.07±2.45, respectively). There were no statistical differences between mean hematological parameters of the groups at the beginning, at the first month, and at the third month, either (mean hb of Group 1: 8.78±1.12 g/dL; 11.27±1.09 g/ dL; 12.05±1.00 g/dL respectively and of Group 2: 9.10±1.07 g/dL; 11.12±0.85 g/dL; 11.80±0.79 g/dL, respectively). Mean ferritin and zinc values of the groups were statistically insignificant at the beginning (Mean ferritin: 4.96±4.03 μg/dL vs 4.52±2.94 μg/dL, zinc: 88.64±15.35 ng/mL vs 86.84±17.34 ng/mL). Their increase was statistically significant at the third month (mean ferritin: 15.91±9.57 μg/dL vs 15.25±10.47 μg/dL; zinc: 88.02±15.10 ng/mL vs 95.25±16.55 ng/mL).>Conclusion: In our study neither positive nor negative effect of zinc administration on IDA treatment was demonstrated. Therefore, in the treatment of IDA zinc together with iron should be used at different times if there is coexistent zinc deficiency.>Conflict of interest:None declared.
展开▼
机译：>目的：在这项研究中，我们旨在比较硫酸锌与缺铁性贫血（IDA）中的硫酸亚铁联合使用对生长和血清铁变量的影响。>材料方法：患者（n = 79）随机分为两组。一组（n = 40）口服4 mg / kg / d的硫酸亚铁。在另一组（n = 39）中，除硫酸亚铁外，口服5 mg / d硫酸锌。>结果：与初始值相比，平均身高，体重和3个月后两组均观察到头围。但是，两组在开始时的平均身高，体重和头围没有统计学差异（83.43±11.3 cm对84.62±12.77 cm; 12.36±3.08 kg对12.72±3.87 kg; 47.33±2.15 cm对47.26±在第一个月分别为2.73厘米（2.73厘米）（84.82±10.97对85.97±12.28; 12.78±3.09对13.09±3.87; 47.76±2.10对47.61±2.67对） 87.69±12.13; 12.9±3.06 vs 13.35±3.81; 48.22±1.89 vs 48.07±2.45）。在开始，第一个月和第三个月，各组的平均血液学参数之间均无统计学差异（第1组的平均hb：8.78±1.12 g / dL； 11.27±1.09 g / dL； 12.05分别为±1.00 g / dL和第2组：分别为9.10±1.07 g / dL，11.12±0.85 g / dL，11.80±0.79 g / dL）。开始时各组的平均铁蛋白和锌值无统计学意义（平均铁蛋白：4.96±4.03μg/ dL vs 4.52±2.94μg/ dL，锌：88.64±15.35 ng / mL vs 86.84±17.34 ng / mL）。它们的增加在第三个月有统计学意义（平均铁蛋白：15.91±9.57μg/ dL与15.25±10.47μg/ dL;锌：88.02±15.10 ng / mL与95.25±16.55 ng / mL）。>结论：< / strong>在我们的研究中，没有发现锌对IDA治疗的正面或负面影响。因此，在IDA的治疗中，如果同时存在锌缺乏症，应在不同时间使用锌和铁。>利益冲突：没有声明。
展开▼
